TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01053637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone/acetaminophen
Description: 0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar water
Description: An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
Study: NCT04878445

Intervention type: PROCEDURE
Intervention: Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.
Description: Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.

Intervention type: PROCEDURE
Intervention: Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.
Description: Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
Study: NCT02357680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU.
Study: NCT02905123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking
Study: NCT04878445

Intervention type: PROCEDURE
Intervention: Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.
Description: Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
Study: NCT00432276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets.
Study: NCT00358956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: 100 mg once daily oral tablet
Study: NCT02244346

Intervention type: DRUG
Intervention: Secotex®
Study: NCT04496505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device
Description: is a mask that uses sequences of flashing lights and analogous sounds to trigger a relaxed state in those with intense pain. Pilot studies have so far shown a statistically significantly decrease in pain, anxiety and opiate withdrawal, as well as an increase in heart rate variability. Preliminary data shows a statistically significant decrease in depression symptoms as measured by Patient Health Questionnaire 9 (PHQ-9) scale .

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham treatment device was designed to copy the look and feel of thetherapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
Study: NCT01264666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese tea flavor liquor
Description: 60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Meijiao liquor

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water control
Study: NCT03089671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B (riboflavin, vitamin B2)
Description: Vitamin B is a natural health product approved as a colouring agent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% Dextrose in Water (D5W)
Description: 5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
Study: NCT01653860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Brøset anger management model
Description: manualised structured cognitive treatment program 15 weeks (30 hours)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary group treatment
Description: group treatment 8 weeks (16 hours)
Study: NCT04109937

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation therapy
Description: The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
Study: NCT03198832

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
Study: NCT00126100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Granulocyte-Colony Stimulating Factor
Description: Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
Study: NCT00655330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan (160mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (160mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol (750mg/day)
Study: NCT02133924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Natalizumab 300mg on days 0 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids
Description: Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
Study: NCT01728805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: 1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Study: NCT01644474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Alirocumab)
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Ezetimibe)
Description: One capsule orally once daily at approximately the same time of the day with or without food..
Study: NCT03763461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.

Intervention type: DEVICE
Group type: OTHER
Intervention: Oxygen Mask
Description: Application of oxygen during conscious sedation
Study: NCT00428051

Intervention type: OTHER
Intervention: Surveillance
Description: No study drug, only interventions are blood draws and Chest X-rays
Study: NCT01000350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo x1 lactose tablet
Study: NCT03320460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propionate clobetasol gel 0.05%
Description: Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo gel
Description: Placebo gel for 30 consecutive days to mask the treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: Laser device will be positioned over the lesion but will be switched off to mask the treatment.
Study: NCT01340911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT3025
Description: SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT3025
Description: SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT3025
Description: SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT3025
Description: SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
Study: NCT03636035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tregocel®
Description: Coated tablet (oral)
Study: NCT03694457

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reversed total shoulder arthroplasty
Description: Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lateral approach
Description: Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
Study: NCT01630343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol tablet and Tramadol capsule
Description: Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panadol 500mg tablet, tramadol 50mg capsule
Description: Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
Study: NCT02244099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Substance
Description: Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
Study: NCT03387514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Description: 18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~* PET2A - Post-surgery and prior to start of standard of care systemic therapy~* PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~* PET3A - Prior to start of additional anti-angiogenesis therapy~* PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy
Study: NCT03136835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maternal Hyperoxygenation
Description: Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
Study: NCT01954524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV bolus injection of Sildenafil
Description: Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
Study: NCT03607903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab ID
Description: Adalimumab intradermal using MicronJet600 microneedle from NanoPass

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab ID
Description: Adalimumab intradermal using MicronJet600 microneedle from NanoPass

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab SC
Description: Adalimumab subcutaneous using regular needle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab SC
Description: Adalimumab subcutaneous using regular needle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline ID
Description: Saline intradermal using MicronJet600 microneedle from NanoPass

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline ID
Description: Saline intradermal using MicronJet600 microneedle from NanoPass

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline SC
Description: Saline subcutaneous using regular needle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline SC
Description: Saline subcutaneous using regular needle
Study: NCT00554333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-ID 15μg
Description: Inactivated Split-Virion Influenza Vaccine for Intradermal Route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated adjuvanted Influenza Vaccine
Description: Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
Study: NCT01159535

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Relapse Prevention
Description: The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention
Description: intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
Study: NCT03461250

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV serology
Description: Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV serology
Description: Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
Study: NCT01740011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Study: NCT01443975

Intervention type: PROCEDURE
Intervention: x-pander
Description: Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
Study: NCT03799679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic Agent
Description: Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV
Study: NCT04156152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION
Description: The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE
Description: The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
Study: NCT04278430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
Study: NCT01213173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinate Metoprolol (Betaloc ZOK®)
Description: treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinate Metoprolol (Betaloc ZOK®)
Description: Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
Study: NCT00012181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study: NCT01156649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP therapy
Description: Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PAP therapy
Description: During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.